Accredo Health Group has been chosen as a specialty pharmacy provider for the new replacement enzyme idursulfase (Elaprase, Shire Genetic Therapies), used to treat Hunter syndrome, a rare, but life-threatening lysosomal storage disorder. Accredo will provide pharmacy management and prescription fulfillment services through its network of 39 pharmacies. Caremark Specialty Pharmacy will be the other provider to distribute the therapy.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.